<?xml version="1.0" encoding="UTF-8"?><bill xmlns="http://schemas.gpo.gov/xml/uslm" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://schemas.gpo.gov/xml/uslm uslm-2.0.10.xsd" xml:lang="en"><meta><dc:title>117 S. 415 ENR: To amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity. </dc:title><dc:type>Senate Bill</dc:type><dc:creator>U.S. Senate</dc:creator><congress>117</congress><session>1</session><docNumber>415</docNumber><docStage>ENR</docStage><citableAs>117s415enr</citableAs><citableAs>117 S. 415 ENR</citableAs><dc:format>text/xml</dc:format><dc:language>EN</dc:language><dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights><processedBy>Xcential BillDTD to USLM Converter v20210601</processedBy><processedDate>2021-11-20</processedDate><publicPrivate>public</publicPrivate></meta><preface><dc:type>S. </dc:type><docNumber>415</docNumber><congress value="117">One Hundred Seventeenth Congress of the United States of America</congress><session value="1">AT THE FIRST SESSION</session><enrolledDateline>Begun and held at the City of Washington on Sunday, the third day of January, two thousand and twenty one</enrolledDateline></preface><main id="H4B890575D1524665A7891A2CE77CF5BE"><longTitle><docTitle>AN ACT</docTitle><officialTitle>To amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity. </officialTitle></longTitle><enactingFormula>Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,</enactingFormula><section identifier="/s1" id="idC2715BAAB1B64BD5B874CD863BB6EB29" class="bill-dtd-OLC"><num value="1">SECTION 1.</num><heading> CLARIFYING THE MEANING OF NEW CHEMICAL ENTITY.</heading><subsection identifier="/s1/a" id="id9458E9587C4C4648AEADD8FCD38E69EB" class="bill-dtd-OLC"><num value="a">(a)</num><heading> In General.—</heading><chapeau>Chapter V of the Federal Food, Drug, and Cosmetic Act is amended—</chapeau><paragraph identifier="/s1/a/1" id="id7585F79C88414A21ACDB9F6D84DAAC61" class="bill-dtd-OLC"><num value="1">(1)</num><chapeau> in section 505 (<ref href="/us/usc/21/355">21 U.S.C. 355</ref>)—</chapeau><subparagraph identifier="/s1/a/1/A" id="id787908CB65B7481683E14837A5D31171" class="bill-dtd-OLC"><num value="A">(A)</num><content> in subsection (c)(3)(E), by striking “<quotedText>active ingredient (including any ester or salt of the active ingredient)</quotedText>” each place it appears and inserting “<quotedText>active moiety (as defined by the Secretary in section 314.3 of title 21, Code of Federal Regulations (or any successor regulations))</quotedText>”;</content></subparagraph><subparagraph identifier="/s1/a/1/B" id="idBE2E3D0759114F2CADE40EDAFA05C3A9" class="bill-dtd-OLC"><num value="B">(B)</num><content> in subsection (j)(5)(F), by striking “<quotedText>active ingredient (including any ester or salt of the active ingredient)</quotedText>” each place it appears and inserting “<quotedText>active moiety (as defined by the Secretary in section 314.3 of title 21, Code of Federal Regulations (or any successor regulations))</quotedText>”;</content></subparagraph><subparagraph identifier="/s1/a/1/C" id="idCB19A1BAAE8F449191B63433744B0C29" class="bill-dtd-OLC"><num value="C">(C)</num><chapeau> in subsection (l)(2)(A)—</chapeau><clause identifier="/s1/a/1/C/i" id="idE750883301E644F09AEF6127CB8BEBFD" class="bill-dtd-OLC"><num value="i">(i)</num><content> by amending clause (i) to read as follows:<quotedContent id="id06C43BC97D9E450F8877B59EEB4A9EEE"><clause identifier="/s1/a/1/C/i/qB/i" id="idC3DA027D83D44CB69321101B36B7A361" class="bill-dtd-OLC"><num value="i">“(i)</num><chapeau> not later than 30 days after the date of approval of such applications—</chapeau><subclause identifier="/s1/a/1/C/i/qB/i/I" id="idFE5D08EFB2BC4606BE21A27E9D382072" class="bill-dtd-OLC"><num value="I">“(I)</num><content> for a drug, no active moiety (as defined by the Secretary in section 314.3 of title 21, Code of Federal Regulations (or any successor regulations)) of which has been approved in any other application under this section; or</content></subclause><subclause identifier="/s1/a/1/C/i/qB/i/II" id="id7D633E2C7D4D4F1FA70D3B5811747587" class="bill-dtd-OLC"><num value="II">“(II)</num><content> for a biological product, no active ingredient of which has been approved in any other application under section 351 of the Public Health Service Act; and”</content></subclause></clause></quotedContent>; and</content></clause><clause identifier="/s1/a/1/C/ii" id="id679a75330d0149f6a296910e6b700bed" class="bill-dtd-OLC"><num value="ii">(ii)</num><content> in clause (ii), by inserting “<quotedText>or biological product</quotedText>” before the period;</content></clause></subparagraph><subparagraph identifier="/s1/a/1/D" id="id9ECB729CE65C4796B91DF05514FF78DF" class="bill-dtd-OLC"><num value="D">(D)</num><content> by amending subsection (s) to read as follows:<quotedContent id="id65DC04D691294FD9956FEC4D3A88118F"><subsection identifier="/s1/a/1/D/qB/s" id="id3E3EE15367F04C959878AE30AA569C22" class="bill-dtd-OLC"><num value="s">“(s)</num><heading> Referral to Advisory Committee.—</heading><chapeau>The Secretary shall—</chapeau><paragraph identifier="/s1/a/1/D/qB/s/1" id="id8d28b559a0924c58afe4a76fb3285b18" class="bill-dtd-OLC"><num value="1">“(1)</num><chapeau> refer a drug or biological product to a Food and Drug Administration advisory committee for review at a meeting of such advisory committee prior to the approval of such drug or biological if it is—</chapeau><subparagraph identifier="/s1/a/1/D/qB/s/1/A" id="id809A90333F4B4639BAFC9BC478C51A87" class="bill-dtd-OLC"><num value="A">“(A)</num><content> a drug, no active moiety (as defined by the Secretary in section 314.3 of title 21, Code of Federal Regulations (or any successor regulations)) of which has been approved in any other application under this section; or</content></subparagraph><subparagraph identifier="/s1/a/1/D/qB/s/1/B" id="id745DC467AC1948F0842460DDB0614842" class="bill-dtd-OLC"><num value="B">“(B)</num><content> a biological product, no active ingredient of which has been approved in any other application under section 351 of the Public Health Service Act; or</content></subparagraph></paragraph><paragraph identifier="/s1/a/1/D/qB/s/2" id="id44E4DDF010FF42BDB9DFFD268A03D8B7" class="bill-dtd-OLC"><num value="2">“(2)</num><content> if the Secretary does not refer a drug or biological product described in paragraph (1) to a Food and Drug Administration advisory committee prior to such approval, provide in the action letter on the application for the drug or biological product a summary of the reasons why the Secretary did not refer the drug or biological product to an advisory committee prior to approval.”</content></paragraph></subsection></quotedContent>; and</content></subparagraph><subparagraph identifier="/s1/a/1/E" id="id4F508551F17C495A8C6780264BE41077" class="bill-dtd-OLC"><num value="E">(E)</num><chapeau> in subsection (u)(1), in the matter preceding subparagraph (A)—</chapeau><clause identifier="/s1/a/1/E/i" id="id20779B2CDCD54E71804B1E2C81DECD10" class="bill-dtd-OLC"><num value="i">(i)</num><content> by striking “<quotedText>active ingredient (including any ester or salt of the active ingredient)</quotedText>” and inserting “<quotedText>active moiety (as defined by the Secretary in section 314.3 of title 21, Code of Federal Regulations (or any successor regulations))</quotedText>”; and</content></clause><clause identifier="/s1/a/1/E/ii" id="idECD971F04743476EB68347D9201870AA" class="bill-dtd-OLC"><num value="ii">(ii)</num><content> by striking “<quotedText>same active ingredient</quotedText>” and inserting “<quotedText>same active moiety</quotedText>”;</content></clause></subparagraph></paragraph><paragraph identifier="/s1/a/2" id="id945738B4834442FF8338C0DFF459D20C" class="bill-dtd-OLC"><num value="2">(2)</num><content> in section 512(c)(2)(F) (<ref href="/us/usc/21/360b">21 U.S.C. 360b(c)(2)(F)</ref>), by striking “<quotedText>active ingredient (including any ester or salt of the active ingredient)</quotedText>” each place it appears and inserting “<quotedText>active moiety (as defined by the Secretary in section 314.3 of title 21, Code of Federal Regulations (or any successor regulations))</quotedText>”;</content></paragraph><paragraph identifier="/s1/a/3" id="id690F570C0BAD4C6F9314D102BDC9621F" class="bill-dtd-OLC"><num value="3">(3)</num><content> in section 524(a)(4) (<ref href="/us/usc/21/360n">21 U.S.C. 360n(a)(4)</ref>), by amending subparagraph (C) to read as follows:<quotedContent id="idA598477551E549A08240F66CA1B5C169"><subparagraph identifier="/s1/a/3/qB/C" id="id4DDECC66A8634FC0B504EAC26D249146" class="bill-dtd-OLC"><num value="C">“(C)</num><chapeau> is for—</chapeau><clause identifier="/s1/a/3/qB/C/i" id="id0BF182F37263466A847D5C275846CF44" class="bill-dtd-OLC"><num value="i">“(i)</num><content> a human drug, no active moiety (as defined by the Secretary in section 314.3 of title 21, Code of Federal Regulations (or any successor regulations)) of which has been approved in any other application under section 505(b)(1); or</content></clause><clause identifier="/s1/a/3/qB/C/ii" id="idA21BDFB480F341EFA1670D9B9603ED38" class="bill-dtd-OLC"><num value="ii">“(ii)</num><content> a biological product, no active ingredient of which has been approved in any other application under section 351 of the Public Health Service Act.”</content></clause></subparagraph></quotedContent>;</content></paragraph><paragraph identifier="/s1/a/4" id="id13155D179D234B70ABF65C67F68B3599" class="bill-dtd-OLC"><num value="4">(4)</num><content> in section 529(a)(4) (<ref href="/us/usc/21/360ff">21 U.S.C. 360ff(a)(4)</ref>), by striking subparagraphs (A) and (B) and inserting the following:<quotedContent id="idB1DE718681AA4881BDF2C3A76181D8B2"><subparagraph identifier="/s1/a/4/qB/A" id="id956c4e4b660f42f3b215d5e0da007414" class="bill-dtd-OLC"><num value="A">“(A)</num><content> is for a drug or biological product that is for the prevention or treatment of a rare pediatric disease;</content></subparagraph><subparagraph identifier="/s1/a/4/qB/B" id="id012ABE5972B94353935175FCDDA03A7F" class="bill-dtd-OLC"><num value="B">“(B)</num><clause identifier="/s1/a/4/qB/B/i" id="id6423E18B61C348A880E3952919B61A8C" class="bill-dtd-OLC"><num value="i">(i)</num><chapeau> is for such a drug—</chapeau><subclause identifier="/s1/a/4/qB/B/i/I" id="idCE3DDC5963A642F4868F7EB07D817AE0" class="bill-dtd-OLC"><num value="I">“(I)</num><content> that contains no active moiety (as defined by the Secretary in section 314.3 of title 21, Code of Federal Regulations (or any successor regulations)) that has been previously approved in any other application under subsection (b)(1), (b)(2), or (j) of section 505; and</content></subclause><subclause identifier="/s1/a/4/qB/B/i/II" id="id6C62C579A331408FA90FDAB6673E70F9" class="bill-dtd-OLC"><num value="II">“(II)</num><content> that is the subject of an application submitted under section 505(b)(1); or</content></subclause></clause><clause identifier="/s1/a/4/qB/B/ii" id="id10FAA061D08B4A79A1403CAA722AEA1A" class="bill-dtd-OLC"><num value="ii">“(ii)</num><chapeau> is for such a biological product—</chapeau><subclause identifier="/s1/a/4/qB/B/ii/I" id="idC455783D540542FFB19B3B88145FD3CD" class="bill-dtd-OLC"><num value="I">“(I)</num><content> that contains no active ingredient that has been previously approved in any other application under section 351(a) or 351(k) of the Public Health Service Act; and</content></subclause><subclause identifier="/s1/a/4/qB/B/ii/II" id="idB75D164BB77942EE96142B78D3FC4757" class="bill-dtd-OLC"><num value="II">“(II)</num><content> that is the subject of an application submitted under section 351(a) of the Public Health Service Act;”</content></subclause></clause></subparagraph></quotedContent>; and</content></paragraph><paragraph identifier="/s1/a/5" id="id360568B3BE934C589AC364F0E29DF0CB" class="bill-dtd-OLC"><num value="5">(5)</num><content> in section 565A(a)(4) (21 U.S.C. 360bbb–4a(a)(4)), by amending subparagraph (D) to read as follows:<quotedContent id="id6B4E38165B0847F7AD76FD9BBA28A1E5"><subparagraph identifier="/s1/a/5/qB/D" id="idB32A2307671A4636A3B620F73A2CC4F5" class="bill-dtd-OLC"><num value="D">“(D)</num><chapeau> is for—</chapeau><clause identifier="/s1/a/5/qB/D/i" id="id6F42087F00E846E3AF050BC4A8610C63" class="bill-dtd-OLC"><num value="i">“(i)</num><content> a human drug, no active moiety (as defined by the Secretary in section 314.3 of title 21, Code of Federal Regulations (or any successor regulations)) of which has been approved in any other application under section 505(b)(1); or</content></clause><clause identifier="/s1/a/5/qB/D/ii" id="id5E6A2B28D82F4C27B78070FBEEA9476E" class="bill-dtd-OLC"><num value="ii">“(ii)</num><content> a biological product, no active ingredient of which has been approved in any other application under section 351 of the Public Health Service Act.”</content></clause></subparagraph></quotedContent>.</content></paragraph></subsection><subsection identifier="/s1/b" id="id8aa5f8f67ac04c0da43ac86167aec18b" class="bill-dtd-OLC"><num value="b">(b)</num><heading> Technical Corrections.—</heading><chapeau>Chapter V of the Federal Food, Drug, and Cosmetic Act (<ref href="/us/usc/21/351">21 U.S.C. 351</ref> et seq.) is amended—</chapeau><paragraph identifier="/s1/b/1" id="id6638d0fd4f234f6d9c5a4e87696fff26" class="bill-dtd-OLC"><num value="1">(1)</num><chapeau> in section 505 (<ref href="/us/usc/21/355">21 U.S.C. 355</ref>)—</chapeau><subparagraph identifier="/s1/b/1/A" id="idd0c2f4ae613d4b6596f42ca2a2e8d607" class="bill-dtd-OLC"><num value="A">(A)</num><content> in subsection (c)(3)(E), by repealing clause (i); and</content></subparagraph><subparagraph identifier="/s1/b/1/B" id="idd6fe3624101e40df8d8e42f60d8b6a95" class="bill-dtd-OLC"><num value="B">(B)</num><content> in subsection (j)(5)(F), by repealing clause (i); and</content></subparagraph></paragraph><paragraph identifier="/s1/b/2" id="idc3a81d30af504595ad8edd8bcf4cd5b6" class="bill-dtd-OLC"><num value="2">(2)</num><content> in section 505A(c)(1)(A)(i)(II) (<ref href="/us/usc/21/355a">21 U.S.C. 355a(c)(1)(A)(i)(II)</ref>), by striking “<quotedText>(c)(3)(D)</quotedText>” and inserting “<quotedText>(c)(3)(E)</quotedText>”. </content></paragraph></subsection></section></main><signatures><signature><name/><role>Speaker of the House of Representatives</role></signature><signature><name/><role>Vice President of the United States and President of the Senate</role></signature></signatures></bill>